UBS Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $415
Benzinga Newsdesk 1 month ago
NewsPrice TargetAnalyst Ratings
UBS analyst Doug Schenkel maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $340 to $415.
UBS analyst Doug Schenkel maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $340 to $415.